TW200602046A - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
TW200602046A
TW200602046A TW094118996A TW94118996A TW200602046A TW 200602046 A TW200602046 A TW 200602046A TW 094118996 A TW094118996 A TW 094118996A TW 94118996 A TW94118996 A TW 94118996A TW 200602046 A TW200602046 A TW 200602046A
Authority
TW
Taiwan
Prior art keywords
group
nr2r3
compounds
carbon atoms
linker group
Prior art date
Application number
TW094118996A
Other languages
Chinese (zh)
Other versions
TWI363622B (en
Inventor
Valerio Berdini
Gordon Saxty
Marinus Leendert Verdonk
Steven John Woodhead
Paul Graham Wyatt
Robert George Boyle
Hannah Fiona Sore
David Winter Walker
Robert Downham
Robin Arthur Ellis Carr
Ian Collins
Original Assignee
Astex Technology Ltd
Cancer Rec Tech Ltd
Cancer Res Inst Royal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2004/005464 external-priority patent/WO2005061463A1/en
Application filed by Astex Technology Ltd, Cancer Rec Tech Ltd, Cancer Res Inst Royal filed Critical Astex Technology Ltd
Publication of TW200602046A publication Critical patent/TW200602046A/en
Application granted granted Critical
Publication of TWI363622B publication Critical patent/TWI363622B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.
TW094118996A 2004-06-08 2005-06-08 Pharmaceutical compounds TWI363622B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57784304P 2004-06-08 2004-06-08
PCT/GB2004/005464 WO2005061463A1 (en) 2003-12-23 2004-12-23 Pyrazole derivatives as protein kinase modulators

Publications (2)

Publication Number Publication Date
TW200602046A true TW200602046A (en) 2006-01-16
TWI363622B TWI363622B (en) 2012-05-11

Family

ID=36940507

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094118996A TWI363622B (en) 2004-06-08 2005-06-08 Pharmaceutical compounds

Country Status (4)

Country Link
AR (1) AR049437A1 (en)
MY (1) MY144464A (en)
SA (1) SA05260179B1 (en)
TW (1) TWI363622B (en)

Also Published As

Publication number Publication date
AR049437A1 (en) 2006-08-02
MY144464A (en) 2011-09-30
TWI363622B (en) 2012-05-11
SA05260179B1 (en) 2009-06-14

Similar Documents

Publication Publication Date Title
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
NO20062633L (en) Pyrazole derivatives as protein kinase modulators
UA93883C2 (en) Pyrazine derivatives useful as adenosine receptor antagonists
TW200611907A (en) Fused heterocyclic compound
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
ATE453639T1 (en) PHENYL SUBSTITUTED PYRIMIDINE COMPOUNDS FOR USE AS KINASE INHIBITORS
TW200833676A (en) Substituted piperidines having protein kinase inhibiting activity
TW200716528A (en) Cyclopropanecarboxamide derivatives
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MX2007006374A (en) 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity.
MY179032A (en) Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2007125315A3 (en) Pharmaceutical compounds
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009013728A (en) Bicycloaniline derivative.
TW200517109A (en) Substituted pyridinones
UA94570C2 (en) Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
TW200612920A (en) Novel imidazolidine derivatives
TNSN07397A1 (en) Acetylene derivatives
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
EA200400466A1 (en) DERIVATIVES OF PIPERAZINE WITH ANTAGONISTIC ACTIVITY TO CCR1 RECEPTOR
MX344276B (en) Novel piperidine compound or salt thereof.
MX2010000658A (en) Pyrimidine derivatives 934.
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees